11.00Average Price Target
The highest estimate is 11.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
This list is based on the watchlists of people on Stock Events who follow AY20.MU. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Show more...
FAQ
What is Aytu BioPharma stock price today?▼
The current price of AY20.MU is €1.94 EUR — it has increased by +0% in the past 24 hours. Watch Aytu BioPharma stock price performance more closely on the chart.
What is Aytu BioPharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Aytu BioPharma stocks are traded under the ticker AY20.MU.
What is Aytu BioPharma market cap?▼
Today Aytu BioPharma has the market capitalization of 20.82M
When is the next Aytu BioPharma earnings date?▼
Aytu BioPharma is going to release the next earnings report on September 29, 2026.
What were Aytu BioPharma earnings last quarter?▼
AY20.MU earnings for the last quarter are -0.45 EUR per share, whereas the estimation was -0.38 EUR resulting in a -19.55% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Aytu BioPharma revenue for the last year?▼
Aytu BioPharma revenue for the last year amounts to 77.77M EUR.
What is Aytu BioPharma net income for the last year?▼
AY20.MU net income for the last year is -9.63M EUR.
In which sector is Aytu BioPharma located?▼
Aytu BioPharma operates in the Other sector.
When did Aytu BioPharma complete a stock split?▼
The last stock split for Aytu BioPharma was on January 06, 2023 with a ratio of 1:20.